1. Product and market-entry snapshot
2. Candidate route questions
Medical-device question
Public clue: The product may monitor or influence user behavior in a health, recovery, or performance context.
Next review question: Confirm intended use and claim wording before deciding whether the product is a device in the target market.
510(k) / licence question
Public clue: If claims move toward diagnosis, treatment, mitigation, or physiological function, product-code or licence-category research may be needed.
Next review question: Search candidate product-code or licensed-device buckets; do not assume comparator suitability.
Wellness / exempt question
Public clue: If the product stays within low-risk general wellness positioning, a different discussion may be possible.
Next review question: Ask a qualified reviewer to compare actual claims against FDA and Health Canada expectations.
3. Market and similar-product context
Market entry is not only a regulatory exercise. The team should know what similar products buyers already see, how those products describe the customer problem, and which messages may require qualified review before use.
- Which public products already tell a similar recovery, performance, or monitoring story?
- Do those products position around wellness experience, clinical workflow, physiological measurement, or treatment outcome?
- Which claims are visible on product pages, labels, manuals, or public summaries?
- Which buyer problem is commercial, and which claim would need qualified review before external use?
4. Consultant meeting prep
The goal is to make the first consultant conversation sharper and cheaper. The founder should bring a clean product summary, public clues, and unresolved review questions.
- Based on the exact intended use statement, is this product likely a medical device, general wellness product, accessory, software function, or something else?
- Which FDA product-code or Health Canada licence-category searches should be reviewed first?
- What public similar-device records should we review before naming candidate comparators?
- What testing, software, cybersecurity, usability, labeling, or clinical evidence questions should be answered before submission planning?
- What claims should sales and marketing avoid until the regulatory strategy is reviewed?